{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-22-000016","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.416256+00:00","generated_at":"2026-06-24T06:12:59.351734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance","bullets":["Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).","Biktarvy sales $2.6B (+28% YoY); oncology sales $527M (+71% YoY) driven by cell therapy and Trodelvy.","HIV product sales $4.2B (+7% YoY); HCV sales $448M (-18% YoY); Veklury sales $445M (-46% YoY).","FY guidance raised: product sales $24.5-25.0B (prev $23.8-24.3B); non-GAAP EPS $6.35-6.75 (prev $6.20-6.70).","Operating cash flow $1.8B in Q2; cash & equivalents $7.0B as of June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-22-000016","json":"https://secwatch.observer/filing/0000882095-22-000016.json","markdown":"https://secwatch.observer/filing/0000882095-22-000016.md","text":"https://secwatch.observer/filing/0000882095-22-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/0000882095-22-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/gild-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:12:59.351734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}